Abstract
The authors discuss a report on the case of symmetrical drug-related intertriginous and flexural exanthema related to the administration of remdesivir in a patient with COVID-19 Topics mentioned include extension of the Consolidated Standards of Reporting Trials (CONSORT) statement for better reporting of harms, adequacy of three clinical trials of remdesivir in COVID-19 fulfilling each of the CONSORT harms recommendations, and potential of remdesivir to cause acute hepatotoxicity
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
